close
close

Hunter Perkins Capital Management LLC Has $3.41 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Hunter Perkins Capital Management LLC Has .41 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Hunter Perkins Capital Management LLC grew its holdings in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 6.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,185 shares of the biopharmaceutical company’s stock after purchasing an additional 2,875 shares during the quarter. Hunter Perkins Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $3,409,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in BMY. Dakota Wealth Management acquired a new position in shares of Bristol-Myers Squibb in the 1st quarter valued at about $332,000. Covestor Ltd raised its stake in Bristol-Myers Squibb by 111.5% during the 1st quarter. Covestor Ltd now owns 2,052 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 1,082 shares during the period. NewEdge Advisors LLC raised its stake in Bristol-Myers Squibb by 53.2% during the 1st quarter. NewEdge Advisors LLC now owns 165,336 shares of the biopharmaceutical company’s stock worth $12,075,000 after buying an additional 57,444 shares during the period. Ergoteles LLC acquired a new position in Bristol-Myers Squibb during the 1st quarter worth approximately $1,997,000. Finally, Mackenzie Financial Corp raised its stake in Bristol-Myers Squibb by 25.1% during the 1st quarter. Mackenzie Financial Corp now owns 338,563 shares of the biopharmaceutical company’s stock worth $24,725,000 after buying an additional 68,018 shares during the period. 74.57% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Rupert Vessey sold 50,385 shares of the company’s stock in a transaction that occurred on Wednesday, May 3rd. The stock was sold at an average price of $67.06, for a total value of $3,378,818.10. Following the transaction, the executive vice president now owns 47,751 shares in the company, valued at $3,202,182.06. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.09% of the stock is owned by company insiders.

See also  Roberto De Zerbi wants to help Jason Steele follow Lewis Dunk into England squad

Bristol-Myers Squibb Stock Performance

BMY stock opened at $65.04 on Friday. The firm has a market cap of $136.64 billion, a PE ratio of 18.96, a P/E/G ratio of 1.33 and a beta of 0.44. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 1.10. The business has a 50 day moving average of $66.70 and a 200-day moving average of $69.74. Bristol-Myers Squibb has a 12-month low of $63.07 and a 12-month high of $81.43.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last posted its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.98 by $0.07. Bristol-Myers Squibb had a return on equity of 51.75% and a net margin of 15.95%. The business had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $11.50 billion. During the same quarter in the prior year, the business earned $1.96 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was down 2.7% on a year-over-year basis. As a group, sell-side analysts expect that Bristol-Myers Squibb will post 8.07 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, August 1st. Investors of record on Friday, July 7th will be paid a $0.57 dividend. The ex-dividend date of this dividend is Thursday, July 6th. This represents a $2.28 annualized dividend and a yield of 3.51%. Bristol-Myers Squibb’s payout ratio is 66.47%.

Analysts Set New Price Targets

BMY has been the topic of a number of research reports. Bank of America upped their price target on Bristol-Myers Squibb from $82.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, April 21st. Barclays dropped their price target on Bristol-Myers Squibb from $66.00 to $65.00 in a research note on Monday, May 1st. Credit Suisse Group decreased their price objective on Bristol-Myers Squibb from $78.00 to $72.00 in a report on Friday, April 28th. Jefferies Financial Group began coverage on Bristol-Myers Squibb in a report on Monday, March 6th. They set a “hold” rating and a $62.00 price objective for the company. Finally, 51job reissued a “maintains” rating on shares of Bristol-Myers Squibb in a report on Friday, April 28th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Moderate Buy” and an average price target of $78.62.

See also  Coventry school apologises for message that 'shames children and parents'

Bristol-Myers Squibb Company Profile

(Get Rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Further Reading

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Bristol-Myers Squibb, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Bristol-Myers Squibb wasn’t on the list.

While Bristol-Myers Squibb currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

If a company’s CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

  • June 25, 2023